Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review
ConclusionsMost evidence indicated sacubitril/valsartan is cost-effective in HFrEF. The use of a lifetime horizon is recommended in future models as HF is a chronic disease. Data on the CE of sacubitril/valsartan in the inpatient setting were limited and further research is warranted.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Australia Health | Cardiology | Cardiovascular | Conferences | Databases & Libraries | Diovan | Economics | Health Management | Heart | Heart Failure | National Institute for Health Research (NIHR) | Study | Websites